BEST of ASCO Portugal 2024 - Gynecological Cancer
Resumo
Foram selecionados 4 estudos para serem apresentados e discutidos na 2ª Reunião Best of ASCO Portugal
Downloads
Referências
– Don S. Dizon et al., Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.. JCO 42, LBA5500-LBA5500(2024). DOI:10.1200/JCO.2024.42.17_suppl.LBA5500
– Anuja Jhingran, Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724.. JCO 42, 5504-5504(2024). DOI:10.1200/JCO.2024.42.16_suppl.5504
– Stephanie Lheureux et al., Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.. JCO 42, 5506-5506(2024). DOI:10.1200/JCO.2024.42.16_suppl.5506
– Angela Green et al., A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.. JCO 42, 5511-5511(2024). DOI:10.1200/JCO.2024.42.16_suppl.5511
